Leal Health Overview
Leal Health is a growing patient-first, AI-powered decision support platform dedicated to expediting access to all available advanced cancer treatments. Working directly with patients, healthcare providers, and pharmaceutical companies, Leal Health provides patients with instant access to precise, advanced cancer treatment while also enabling the pharmaceutical and biotech industries to develop patient-centric clinical trials and provide real-time analytics and understanding of patient barriers and motivations. Leal Health was chosen as one of TIME magazine’s “100 Best Inventions of 2020,” was named an honoree in Fast Company’s 2021 “World-Changing Ideas Awards” in the AI and data category, and recognized as the “Leader in Patient Recruitment and Enrollment” by CBInsights.
Cumulative Funding Raised Over Time ($)
$500K
$26.5MApr 2024
$29.2MDec 2019
$34.2MFeb 2021
$54.2MFeb 2022
Latest News
growth-positive
Leal Health boosts patient platform to include 'generative' AI
Leal Health, an AI-powered health tech firm, has enhanced its cancer-care-focused patient platform by integrating generative AI. This upgrade aims to improve the prediction of patient treatment regimens based on their medical history and current conditions. The integration is expected to help healthcare providers identify and educate potential patients more effectively. Despite challenges associated with generative AI, such as understanding unique patient journeys and errors, Leal Health has successfully combined AI technologies to analyze complex medical conditions accurately. The platform also aims to make cancer treatments more accessible to patients. Leal Health, formerly known as Trialjectory, has been involved in over 3.5 million treatment matches and adds over 4,000 new cancer patients monthly.
Customers
growth-positive
Leal Health adds a 'first' with FDA-approved cancer treatment decision support service
Leal Health, formerly known as Trialjectory, has expanded its AI-powered platform to include FDA-approved cancer treatment decision support. This marks the first time patients have a single access point to explore personalized treatment options, including standard care and clinical trials. The platform integrates real-world data to match patients with suitable treatments based on their medical profiles. Leal Health reports that it has facilitated over 3.5 million treatment matches and is adding more than 4,000 new cancer patients monthly. This expansion is expected to enhance patient empowerment and streamline the decision-making process for cancer treatments.
CustomersExpand
growth-positive
New Trialjectory Data Shows Triple-Negative Breast Cancer Patients More Likely to Seek Clinical Trial Options Prior to Treatment for Advanced Disease
Trialjectory, an AI-powered decision support platform, presented new data at the San Antonio Breast Cancer Symposium showing that triple-negative breast cancer (TNBC) patients are more likely to seek clinical trial options for their disease compared to other subtypes. The data also revealed that TNBC patients initiate their clinical trial search earlier in their cancer journey and are willing to travel any distance within the U.S. to enroll in a clinical trial. The findings highlight the need for effective treatments for TNBC and the motivation of patients to participate in clinical trials. Trialjectory aims to improve cancer treatment by democratizing access to advanced therapies and making clinical trials more patient-centric.
Customers
growth-positive
Trialjectory Grows Pharmaceutical and Biotech Clinical Trial Partnerships by 800 Percent
Trialjectory, an AI-powered decision support platform, has announced that it is currently working with over 50 pharmaceutical companies, emerging biotechs, and Contract Research Organizations to develop and execute patient-centric clinical trials. By understanding the patients perspective, Trialjectory aims to improve trial design and execution, resulting in increased patient enrollment and expedited drug development timelines. The company has experienced significant growth, with a database of over 20,000 trials and over 4,000 new cancer patients joining the platform each month. Trialjectory has also tripled its revenue from new pharmaceutical customers and exceeded its 2021 revenue in just the first half of 2022. The company provides real-time patient data and has achieved positive outcomes, including providing more qualified patient leads, reducing enrollment timelines, and improving minority patient representation in clinical trials.
PartnersCustomersInvestment
growth-positive
Trialjectory Boasts Over 54 Percent Growth in New Cancer Patient Users from Diverse Ethnic and Racial Backgrounds in Q1 2022
Trialjectory, an AI-powered decision-support platform for patients, healthcare providers, and pharmaceutical companies, has experienced over 54 percent growth in new cancer patient users from diverse ethnic and racial backgrounds in Q1 2022. This growth is in line with new FDA guidelines that mandate pharmaceutical companies to enroll more diverse patient populations in clinical trials. Trialjectorys platform allows pharmaceutical companies to obtain more diverse qualified patient leads, receive real-time demographic data, pinpoint eligibility criteria barriers, and get recommendations on additional site locations for clinical trials. The companys commitment to diversity in clinical trials aligns with the FDAs guidelines and aims to bridge the gap between the pharmaceutical industry and patients. Trialjectory has been recognized for its innovation and impact in the oncology drug development ecosystem.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $54.2M |
| Last funding | $26M |
| Stage | B |
| Rounds | 6 |
| Investors | 8 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | www.leal.health/ |
Locations
King George Street 48, Tel Aviv-Yafo, Israel
700 Canal St, Stamford, CT, USA
Photos & Videos
5 item(s)
Leal Health Business
Business models
B2B, B2B2C
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcarePatient EngagementRetail PlatformsServicesTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProvidersPatientsCore Technology
Platforms & InterfacesSoftwareArtificial IntelligenceTags (18)
saasdecision-supportmachine-learningpatientspharma-companiesoncologymarketplaceactionable-insightsartificial-intelligencedoctorscancernatural-language-processingdeep-learningdigital-healthcareweb-platformclinical-datapatient-engagementclinical-trialsGeographic Markets
United StatesLeal Health Financials
$54.2M
Total funding
Undisclosed
Capital raised
$26M
Last funding
B
Funding stage
6
Total rounds
8
Investors
Cumulative Funding Raised Over Time ($)
$500K
$26.5MApr 2024
$29.2MDec 2019
$34.2MFeb 2021
$54.2MFeb 2022
Private Equity Funding
B Round
Apr 2024
$26M
Ineffable Ventures (Lead)
A Round
Feb 2022
$20M
Insight Partners (Lead)
,
Contour Venture Partners, TIA Ventures, Rho Capital Partners, JAL Ventures
A Round
Feb 2021
$5M
Contour Venture Partners (Lead)
,
Connecticut Innovations, TIA Ventures, Rho Capital Partners
Seed
Dec 2019
$2.7M
Contour Venture Partners (Lead)
Undisclosed Round
$500K
Undisclosed Investor(s)
Non-Equity Funding
GrantEvent
Sep 2021
Undisclosed
BIRD Foundation
Leal Health Lifecycle
Cumulative Funding Raised Over Time
$500K
$26.5MApr 2024
$29.2MDec 2019
$34.2MFeb 2021
$54.2MFeb 2022
All Events
B Round
Apr 2024
$26M
Ineffable Ventures (Lead)
A Round
Feb 2022
$20M
Insight Partners (Lead)
,
Contour Venture Partners, TIA Ventures, Rho Capital Partners, JAL Ventures
A Round
Feb 2021
$5M
Contour Venture Partners (Lead)
,
Connecticut Innovations, TIA Ventures, Rho Capital Partners
Seed
Dec 2019
$2.7M
Contour Venture Partners (Lead)
Undisclosed Round
$500K
Undisclosed Investor(s)
GrantEvent
Sep 2021
Undisclosed
BIRD Foundation
Leal Health News
17 articles
growth-positive
Leal Health boosts patient platform to include 'generative' AI
Leal Health, an AI-powered health tech firm, has enhanced its cancer-care-focused patient platform by integrating generative AI. This upgrade aims to improve the prediction of patient treatment regimens based on their medical history and current conditions. The integration is expected to help healthcare providers identify and educate potential patients more effectively. Despite challenges associated with generative AI, such as understanding unique patient journeys and errors, Leal Health has successfully combined AI technologies to analyze complex medical conditions accurately. The platform also aims to make cancer treatments more accessible to patients. Leal Health, formerly known as Trialjectory, has been involved in over 3.5 million treatment matches and adds over 4,000 new cancer patients monthly.
Customers
growth-positive
Leal Health adds a 'first' with FDA-approved cancer treatment decision support service
Leal Health, formerly known as Trialjectory, has expanded its AI-powered platform to include FDA-approved cancer treatment decision support. This marks the first time patients have a single access point to explore personalized treatment options, including standard care and clinical trials. The platform integrates real-world data to match patients with suitable treatments based on their medical profiles. Leal Health reports that it has facilitated over 3.5 million treatment matches and is adding more than 4,000 new cancer patients monthly. This expansion is expected to enhance patient empowerment and streamline the decision-making process for cancer treatments.
CustomersExpand
growth-positive
New Trialjectory Data Shows Triple-Negative Breast Cancer Patients More Likely to Seek Clinical Trial Options Prior to Treatment for Advanced Disease
Trialjectory, an AI-powered decision support platform, presented new data at the San Antonio Breast Cancer Symposium showing that triple-negative breast cancer (TNBC) patients are more likely to seek clinical trial options for their disease compared to other subtypes. The data also revealed that TNBC patients initiate their clinical trial search earlier in their cancer journey and are willing to travel any distance within the U.S. to enroll in a clinical trial. The findings highlight the need for effective treatments for TNBC and the motivation of patients to participate in clinical trials. Trialjectory aims to improve cancer treatment by democratizing access to advanced therapies and making clinical trials more patient-centric.
Customers
growth-positive
Trialjectory Grows Pharmaceutical and Biotech Clinical Trial Partnerships by 800 Percent
Trialjectory, an AI-powered decision support platform, has announced that it is currently working with over 50 pharmaceutical companies, emerging biotechs, and Contract Research Organizations to develop and execute patient-centric clinical trials. By understanding the patients perspective, Trialjectory aims to improve trial design and execution, resulting in increased patient enrollment and expedited drug development timelines. The company has experienced significant growth, with a database of over 20,000 trials and over 4,000 new cancer patients joining the platform each month. Trialjectory has also tripled its revenue from new pharmaceutical customers and exceeded its 2021 revenue in just the first half of 2022. The company provides real-time patient data and has achieved positive outcomes, including providing more qualified patient leads, reducing enrollment timelines, and improving minority patient representation in clinical trials.
PartnersCustomersInvestment
growth-positive
Trialjectory Boasts Over 54 Percent Growth in New Cancer Patient Users from Diverse Ethnic and Racial Backgrounds in Q1 2022
Trialjectory, an AI-powered decision-support platform for patients, healthcare providers, and pharmaceutical companies, has experienced over 54 percent growth in new cancer patient users from diverse ethnic and racial backgrounds in Q1 2022. This growth is in line with new FDA guidelines that mandate pharmaceutical companies to enroll more diverse patient populations in clinical trials. Trialjectorys platform allows pharmaceutical companies to obtain more diverse qualified patient leads, receive real-time demographic data, pinpoint eligibility criteria barriers, and get recommendations on additional site locations for clinical trials. The companys commitment to diversity in clinical trials aligns with the FDAs guidelines and aims to bridge the gap between the pharmaceutical industry and patients. Trialjectory has been recognized for its innovation and impact in the oncology drug development ecosystem.
Customers
growth-positive
Trialjectory Presents Poster Highlighting Platform's Effective Cancer Patient Clinical Trial Recruitment at 2022 ASCO Annual Meeting
Trialjectory, an AI-powered decision-support platform, presented a poster at the American Society of Clinical Oncology Annual Meeting on cancer patients clinical trial participation. The poster highlighted the platforms effectiveness in offering patients and doctors direct access to relevant clinical trials, resulting in higher engagement and enrollment rates. Trialjectory has over 65,000 cancer patient members, with 4,000 new sign-ups per month and over 1 million clinical trial matches made to date. The platform uses AI and machine learning to match patients to the most relevant clinical trials. Trialjectorys patient-centric approach increases patient participation and accelerates the drug development process for pharmaceutical companies. The company has been recognized as one of the best inventions of 2020 and an honoree in the AI and data category for the 2021 World-Changing Ideas Awards.
CustomersPartners
growth-positive
Trialjectory scores $20M to match cancer patients to clinical trials
Trialjectory, a startup that matches cancer patients to clinical trials, has raised $20 million in Series A funding. The company offers an AI-enabled platform for patients to input information about their cancer and be matched to open clinical trials. Trialjectory also works with pharmaceutical companies to recruit patients and build trials with diverse populations. The funding round was led by Insight Partners, with participation from other venture capital firms. The company aims to remove barriers and biases in accessing advanced treatment options for cancer patients.
Investment
growth-positive
Trialjectory on track to match 50K cancer patients with clinical trials this year: 35% are from underrepresented groups
Trialjectory, a company that matches cancer patients to clinical trials, has experienced significant growth in the number of patients on its platform. The company aims to address the underrepresentation of women and ethnic minorities in cancer trials. It has seen a rise in membership from 2,000 in 2019 to an expected 50,000 in 2021. Trialjectory has been successful in reaching underrepresented groups, with 35% of its patients coming from these backgrounds. The companys growth strategy involves creating patient communities, providing educational content, and leveraging patient champions to share information. Trialjectory aims to empower patients to take ownership of their treatment decisions and navigate their cancer care journey. By offering patient-friendly information about clinical trials and providing support, the company helps remove barriers and encourages patients to explore their options.
Customers
growth-positive
YonaLink, TrialJectory get $1m grant for patient recruitment tool -
YonaLink and TrialJectory have received a grant to develop a tool that automates the conduct of clinical trials, aiming to reduce cost, time, and resources. The tool will screen patients and connect them to trial sites, eliminating manual processes involved in data management and patient enrolment. The grant from the BIRD Foundation will support the further development of the platform. The joint project between the two companies aims to shift the focus of clinical trials from site-oriented to patient-oriented. The tool developed by TrialJectory uses artificial intelligence to match cancer patients with trials and provide support, while YonaLinks platform adds real-time streaming data to enhance data management. The companies claim that the tool can reduce trial costs by 30% and save months in data management, cleansing, and analysis.
PartnersInvestment
growth-positive
Clinical Trial Matching Startup's Survey Spotlights NGS Access Barriers, Patient Awareness
Digital health startup TrialJectory conducted a survey revealing that while most cancer patients understand the importance of genetic testing, less than half have undergone multigene next-generation sequencing (NGS) to identify actionable biomarkers. The survey results showed that 90% of patients understood the importance of biomarker testing, but many did not get tested due to doctors beliefs that testing wouldnt identify actionable markers or because insurance wouldnt cover it. TrialJectory is exploring partnerships with diagnostics firms to help patients access NGS testing. The companys platform matches patients to clinical trial options and provides valuable deidentified patient data to trial sponsors. TrialJectory is rapidly growing its patient numbers and expects to form more partnerships in the future.
Customers
growth-positive
Startup Helps Cancer Patients Find Clinical Trials, Offering New Hope And More Options
The article discusses how cancer patients are taking charge of their care and seeking out clinical trials and advanced treatment options. It highlights the platform TrialJectory, which uses artificial intelligence to connect cancer patients with clinical trials. The pandemic has inspired more patients to be involved in their treatment decisions and search for treatment options beyond their doctors guidance. The article also mentions the importance of genetic testing in cancer treatment and the barriers patients face in accessing it. Overall, the impact on TrialJectory is growth-positive as more patients are interested in participating in clinical trials and using the platform.
Customers
growth-positive
Tzvia Bader Discusses the TrialJectory Platform Connecting Patients With Cancer to Clinical Trials
CancerNetwork® spoke with Tzvia Bader about TrialJectory, an AI-powered platform that matches cancer patients with clinical trials. The platform aims to lower barriers to inclusion of a more diverse patient population in trials and facilitate progress in the pharmaceutical industry. TrialJectory helps patients take a proactive role in their treatment and provides information on viable treatment options. It also addresses the issue of limited clinical trial discussions between community oncologists and their patients. The article highlights the importance of activated patients and their ability to contribute valuable insights into their own treatment. The platform is expected to have a positive impact on TrialJectorys growth.
CustomersPartners
growth-positive
TrialJectory Achieves 500 Percent Year-Over-Year Growth as Cancer Patients and Pharmaceutical Industry Increasingly Leverage Proprietary AI Platform in COVID-19 Pandemic
TrialJectory, an AI-powered digital health platform, has experienced 500 percent year-over-year growth in new patient users. The company has also increased collaborations with pharmaceutical companies and CROs. To support its growth, TrialJectory recently completed a $5 million Series A financing round led by Contour Venture Partners. The company has raised a total of $8 million to date. TrialJectorys technology provides personalized treatment options for cancer patients and helps match them with clinical trials. The platform uses AI to curate and personalize large amounts of cancer research data. TrialJectory aims to empower patients and improve the overall clinical trial development process. The company is recognized for its role in democratizing access to advanced cancer treatment.
CustomersPartnersInvestment
growth-positive
TIME Selects TrialJectory's AI-Powered, Clinical Trial-Matching Platform for '100 Best Inventions of 2020' List
TrialJectory, an AI-powered digital health platform for cancer patients, has been selected by TIME for its 100 Best Inventions of 2020 annual list. The platform helps cancer patients find advanced treatment options through clinical trial-matching and provides real-world treatment data from other patients with similar profiles. TrialJectorys SaaS intelligence platform, Patient Match Optimizer, allows pharmaceutical companies to identify patient barriers in participating in clinical trials and optimize trial design. The recognition by TIME highlights the impact and effectiveness of TrialJectorys patient-first approach and AI technology in democratizing access to advanced cancer treatment.
CustomersPartners
growth-positive
TrialJectory and Precipio Partner to Provide Cancer Patients with First-of-its-Kind Diagnostic and Clinical Trial-Matching Service
TrialJectory has announced a new partnership with Precipio to provide cancer patients with a diagnostic and clinical trial-matching service. The partnership aims to improve patient treatment outcomes by combining the innovations of both companies. Precipios diagnostic result reports will now include a personalized list of relevant clinical trials matched to the patient based on TrialJectorys AI-based platform. The platform uses patient clinical information to facilitate the clinical trial search, matching, and enrollment process. TrialJectory will handle communication with the clinical trial lead on behalf of the patient. The partnership allows patients to have more control over their health and make informed decisions based on accurate information.
Partners
growth-positive
Trialjectory uses self-reported clinical data to match cancer patients with clinical trials
Trialjectory, a company developing a technology service to match cancer patients with clinical trials, has raised $2.7 million in funding. The financing will be used to expand the companys operations, add more clinical trials for different cancer types, and increase outreach to caregivers, pharmaceutical companies, and patients. Trialjectorys software uses keyword recognition and data extraction to create a database of patient attributes for clinical trials. Patients are then matched to trials based on a questionnaire. The funding round was led by Contour Venture Partners, who believe that Trialjectory has the potential to become a go-to resource for personalized treatment options in the global medical community.
InvestmentExpand
growth-positive
This Startup Helps Patients Find their Best Shot at Surviving Cancer
TrialJectory, a startup that helps patients find the right treatment for cancer through clinical trials, is experiencing growth-positive impact. The key theme of the article is the difficulty patients face in navigating clinical trials and the solution provided by TrialJectory. The key issues discussed in the article are customers and investment. The article does not mention any specific partners or customers. The company has raised over $500,000 to date and plans to raise up to $1 million in the upcoming months. The event described in the article is ongoing. The confidence level of the answer is 8.
CustomersInvestment
Leal Health Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 21 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 14 classification IDs that could be used for matching.
Leal Health Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Natalia Golczar |
| Registrar ID | 516091030 |
| Crunchbase | trialjectory |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-02-20T00:00:00.000Z |
| Created | 2018-11-05T00:00:00.000Z |
| Claimed | Yes |